|
1
|
Hudis CA and Gianni L: Triple-negative
breast cancer: An unmet medical need. Oncologist. 16 (Suppl
1):S1–S11. 2011. View Article : Google Scholar
|
|
2
|
Cortazar P, Zhang L, Untch M, Mehta K,
Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L,
Valagussa P, et al: Pathological complete response and long-term
clinical benefit in breast cancer: The CTNeoBC pooled analysis.
Lancet. 384:164–172. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schmid P, Cortes J, Pusztai L, McArthur H,
Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, et al:
Pembrolizumab for early triple-negative breast cancer. N Engl J
Med. 382:810–821. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schmid P, Cortes J, Dent R, Pusztai L,
McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, et al:
Event-free survival with pembrolizumab in early triple-negative
breast cancer. N Engl J Med. 386:556–567. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang DY, Salem JE, Cohen JV, Chandra S,
Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, et al: Fatal
toxic effects associated with immune checkpoint inhibitors: A
systematic review and meta-analysis. JAMA Oncol. 4:1721–178. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kramer R, Zaremba A, Moreira A, Ugurel S,
Johnson DB, Hassel JC, Salzmann M, Gesierich A, Weppler A, Spain L,
et al: Hematological immune related adverse events after treatment
with immune checkpoint inhibitors. Eur J Cancer. 147:170–181. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fardet L, Galicier L, Lambotte O, Marzac
C, Aumont C, Chahwan D, Coppo P and Hejblum G: Development and
validation of the HScore, a score for the diagnosis of reactive
hemophagocytic syndrome. Arthritis Rheumatol. 66:2613–2620. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Henter JI, Horne A, Aricó M, Egeler RM,
Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski
J and Janka G: HLH-2004: Diagnostic and therapeutic guidelines for
hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer.
48:124–131. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dupré A, Michot JM, Schoeffler A,
Frumholtz L, Baroudjian B, Delyon J, Lebbe C and Lambotte O:
Haemophagocytic lymphohistiocytosis associated with immune
checkpoint inhibitors: A descriptive case study and literature
review. Br J Haematol. 189:985–992. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Noseda R, Bertoli R, Müller L and Ceschi
A: Haemophagocytic lymphohistiocytosis in patients treated with
immune checkpoint inhibitors: Analysis of WHO global database of
individual case safety reports. J Immunother Cancer. 7:1172019.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Planas R, Felber M, Vavassori S and
Pachlopnik Schmid J: The hyperinflammatory spectrum: From defects
in cytotoxicity to cytokine control. Front Immunol. 14:11633162023.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Brahmer JR, Abu-Sbeih H, Ascierto PA,
Brufsky J, Cappelli LC, Cortazar FB, Gerber DE, Hamad L, Hansen E,
Johnson DB, et al: Society for Immunotherapy of Cancer (SITC)
clinical practice guideline on immune checkpoint inhibitor-related
adverse events. J Immunother Cancer. 9:e0024352021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Michot JM, Lazarovici J, Tieu A, Champiat
S, Voisin AL, Ebbo M, Godeau B, Michel M, Ribrag V and Lambotte O:
Haematological immune-related adverse events with immune checkpoint
inhibitors, how to manage? Eur J Cancer. 122:72–90. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Faleck DM, Dougan M, Tello M, Grossman JE,
Moss AC and Postow MA: Accelerating the evolution of immune-related
enterocolitis management. J Clin Oncol. 41:3110–3115. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kurozumi A, Takahashi H, Watanabe T and
Iwasaki Y: Two cases of lung cancer with hemophagocytic
lymphohistiocytosis caused by immune checkpoint inhibitors. Thorac
Cancer. 12:1625–168. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sackstein P, Zaemes J and Kim C:
Pembrolizumab-induced cytokine release syndrome in a patient with
metastatic lung adenocarcinoma: A case report. J Immunother Cancer.
9:e0028552021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Okawa S, Kayatani H, Fujiwara K, Ozeki T,
Takada K, Iwamoto Y, Minami D, Sato K and Shibayama T:
Pembrolizumab-induced autoimmune hemolytic anemia and
hemophagocytic lymphohistiocytosis in non-small cell lung cancer.
Intern Med. 58:699–702. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Laderian B, Koehn K, Holman C, Lyckholm L
and Furqan M: Association of hemophagocytic lymphohistiocytosis and
programmed death 1 checkpoint inhibitors. J Thorac Oncol.
14:e77–e78. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Honjo O, Kubo T, Sugaya F, Nishizaka T,
Kato K, Hirohashi Y, Takahashi H and Torigoe T: Severe cytokine
release syndrome resulting in purpura fulminans despite successful
response to nivolumab therapy in a patient with pleomorphic
carcinoma of the lung: A case report. J Immunother Cancer.
7:972019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hantel A, Gabster B, Cheng JX, Golomb H
and Gajewski TF: Severe hemophagocytic lymphohistiocytosis in a
melanoma patient treated with ipilimumab + nivolumab. J Immunother
Cancer. 6:732018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Satzger I, Ivanyi P, Länger F, Kreipe HH,
Schaper-Gerhardt K, Beutel G, Cornberg M and Gutzmer R:
Treatment-related hemophagocytic lymphohistiocytosis secondary to
checkpoint inhibition with nivolumab plus ipilimumab. Eur J Cancer.
93:150–153. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sadaat M and Jang S: Hemophagocytic
lymphohistiocytosis with immunotherapy: Brief review and case
report. J Immunother Cancer. 6:492018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Takeshita M, Anai S, Mishima S and Inoue
K: Coincidence of immunotherapy-associated hemophagocytic syndrome
and rapid tumor regression. Ann Oncol. 28:186–189. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Malissen N, Lacotte J, Du-Thanh A,
Gaudy-Marqueste C, Guillot B and Grob JJ: Macrophage activation
syndrome: A new complication of checkpoint inhibitors. Eur J
Cancer. 77:88–89. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shah D, Shrestha R, Ramlal R, Hatton J and
Saeed H: Pembrolizumab associated hemophagocytic
lymphohistiocytosis. Ann Oncol. 28:14032017. View Article : Google Scholar : PubMed/NCBI
|
